About Us

Finding new & better treatments for Type 1 Diabetes

Who We Are

Type 1 Diabetes UK Immunotherapy Consortium (T1D UK) was set up in 2015 with major funding from Diabetes UK & the JDRF, to promote, develop and support immunotherapy research in T1D.

T1D UK will establish and train a network of 15 Level 1 Research Sites strategically distributed across the UK that will work in partnership with the ADDRESS 2 recruitment infrastructure.

There are 2 main cores to T1D UK, a clinical engagement & training core (CET) led by Prof Colin Dayan from Cardiff University and a mechanistic core with 5 specialist Labs located throughout the UK, led by Tim Tree from Kings College, London.

Principal Aim

To help get immune therapy into the market as part of the management for type 1 diabetes.

The Vision

An improved environment for immune therapy trials in the UK: rapid, early and enhanced patient recruitment; enhanced academic engagement with trial design; the provision of a mechanistic core.

The Clinical Engagement & Training Core

The aim of the CET team is to support recruitment into immune therapy trials. The team will co-ordinate and promote trials to Research Sites, engage with teams at the sites and develop and deliver a training programme for research and clinical teams at sites.

Mechanistic Core

The mechanistic core brings together experts in the immunology of T1D from 5 different labs across the UK: Bristol, Cardiff, Oxford, King’s College London, & Queen Mary’s London. These laboratories will provide state of the art immunological assays that will study the impact of immune therapy trials, investigating exactly how different treatments work to control the immune attack that causes type 1 diabetes and working out if it is possible to predict who will benefit from each treatment.

T1D UK Consortium Meeting

28/11/2016 – Blizard Institute, London

Researchers and Health Care Professionals at a T1D UK Scientific Meeting held at the Blizard Institute in London on 28/11/16

Meet some of the members of T1D UK as they talk about their interest in type 1 diabetes and their role in the T1D UK Immunotherapy Consortium